Compare FNWB & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FNWB | IMUX |
|---|---|---|
| Founded | 1923 | 2016 |
| Country | United States | United States |
| Employees | N/A | 66 |
| Industry | Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 96.3M | 155.8M |
| IPO Year | 2012 | 2013 |
| Metric | FNWB | IMUX |
|---|---|---|
| Price | $10.26 | $10.35 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | $13.50 | ★ $36.00 |
| AVG Volume (30 Days) | 18.0K | ★ 252.4K |
| Earning Date | 04-29-2026 | 05-14-2026 |
| Dividend Yield | ★ 0.70% | N/A |
| EPS Growth | 36.00 | ★ 38.00 |
| EPS | ★ 0.04 | N/A |
| Revenue | ★ $176,000.00 | N/A |
| Revenue This Year | $19.24 | N/A |
| Revenue Next Year | $8.90 | N/A |
| P/E Ratio | $261.25 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.25 | $0.51 |
| 52 Week High | $12.52 | $17.43 |
| Indicator | FNWB | IMUX |
|---|---|---|
| Relative Strength Index (RSI) | 26.01 | 28.05 |
| Support Level | $9.55 | $0.76 |
| Resistance Level | $10.38 | $15.82 |
| Average True Range (ATR) | 0.26 | 1.04 |
| MACD | -0.08 | -0.48 |
| Stochastic Oscillator | 11.02 | 2.38 |
First Northwest Bancorp is a bank holding company and a financial holding company and is engaged in banking activities through its wholly owned subsidiary, First Fed Bank, as well as certain non-banking financial activities. It offers various products and services, such as commercial business loans, multi-family real estate loans, auto and consumer loans, transaction accounts, savings and money market accounts, online banking services, etc., focused on the lending, deposit, and money movement needs of individuals, businesses and nonprofit organizations. The Group's operations are mainly focused on serving various communities in Washington State, U.S. Substantially all of its income is derived from a diverse base of commercial, mortgage, and consumer lending activities and investments.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.